pocketful logo
Fermenta Biotech Ltd logo

Fermenta Biotech Ltd

NSE: BSE: 506414

₹307.40

(0.34%)

Thu, 21 May 2026, 05:27 pm

mtf coin illustrationMTF 5x

Company History

1951

  • The company was Incorporated on 1st May as a private limited company under the name International Franchise Pvt.
  • DIL was promoted by Solvay Pharmaceuticals based Brussels and Mr. D. Vasant Kumar and family in India.

1962

  • The Collaboration agreements were concluded with N.V. Philips-Duphar of Amsterdam and the Crookes Laboratories Ltd., London.

1967

  • The first phase of vitamin D manufacture was undertaken.
  • Import substitution was implemented in certain chemicals.
  • 1,200 No. of equity shares were issued at par in prop. 1:2.

1971

  • The name of the Company was changed to Duphar-Interfran Ltd.

1975

  • The second phase of vitamin D was implemented.
  • The Company's products included Crookes' transfusion, crocin and lacto-calamine.
  • 36,000 bonus shares were issued in prop. 1:1.

1977

  • 2,00,000 shares were offered to the public at a premium of Rs 2.50 per share.

1979

  • The Company undertook to set up a joint venture company under the name Fermentapharma Biodil Ltd.

1984

  • A modernisation and replacement programme was taken up at the cost of Rs 100 lakhs.
  • 4,60,000 bonus equity shares were issued in prop. 1:2.

1985

  • Profitability was affected by a strike in the Vapi unit.
  • The Company obtained registration for the manufacture of some bulk drugs and their formulations.

1988

  • The Company privately placed 1,20,000-14% non-convertible debentures of Rs 100 each for Rs 120 lakhs.
  • 4,60,000 bonus shares were issued in prop. 1:3.

1991

  • 3,22,000 shares were issued at a premium of Rs 35 per share.
  • 3,06,667 shares were issued on rights basis and 15,333 shares to employees.

1992

  • The Company continued to concentrate towards development of new formulation, bulk drugs and intermediates.
  • The Company proposed to set up a third manufacturing unit at Takwe, Maharashtra.
  • The Company introduced Vitamin D3 combination for veterinary use and Amoxycillin Dispersible Tablet.
  • The Company developed chemical preparation of Sulbactam, a beta-lactamase inhibitor.

1993

  • The Company undertook expansion programme by recreating its Vitamin D3 plant at Thane.
  • Vitamin D3 preparation in Arachis Oil for Animal Feed was developed.
  • The Company's Pilot Plant was engaged in the scaling up of in-house processes for Sulbactam and Chlorzoxazone.

1994

  • The Company proposed to issue New Equity Shares of Rs. 10/- each as Rights Shares at a premium of Rs.45 per share.
  • Two new bulk drugs namely Chlorzoxazone and Sulbactam Sodium were successfully manufactured on commercial scale.
  • Vitamin D3, liquid formulation for Animal Feed was developed and launched in the market.

1995

  • The Company offered equity shares of Rs 10 each at a premium of Rs 45 per share on rights basis to the existing shareholders.
  • The Company set up a third manufacturing unit at village Takwe (Budruk), Taluka - Maval, District - Pune.

1996

  • The Company effected sale of its main product namely, Crocin range.
  • The Company launched one of the Gynaec products under the brand name Yutopar.
  • The Company introduced Voluntary Retirement Scheme for its workmen and staff members at Thane Factory and Head Office.

1997

  • The Company launched a new product under the brand name UDILIV for chronic hepatitis, cholestasis and dissolution of gall stones indications.
  • The Company has an R & D Laboratory approved by DSIR for chemicals and pharmaceutical research and development activity.
  • A wage settlement was signed with Unions of Medical Representatives and a wage agreement with the Union of Thane and H.O. Workmen and Staff.

1998

  • Duphar-Interfran is present in categories like antibiotics, anti-stress therapy, iodine therapy and muscle spasm.
  • The company launched a product under the brand name Udiliv for chronic hepatitis, cholestasis and dissolution of gall stones indications.

1999

  • The Company continued research programme for finding out new lead molecules of medicinal importance and development of indigenous technologies for major drugs and intermediates.
  • The Company installed electrical capacitors to maintain power factor at an efficient level.
  • The Company has an extensive computer network.

2000

  • Duphar-Interfran Ltd said it is demerging its pharmaceutical business into a new company.
  • The Company signed agreements with NSDL and CDSL for dematerialisation of the company's shares and for electronic connectivity.

2002

  • Mr Kunal Kashyap was appointed as a Director on the Board of the company.

2005

  • The Registered Office of the Company was shifted from Worli, Mumbai to Thane.

2007

  • Dil Ltd appointed Mr. Sanjay Buch as an additional director (Independent Category).

2008

  • Dil Ltd recommended an equity dividend of 100%.

2009

  • Dil Ltd declared Interim Dividend and recommended Final Dividend of Rs 7.50 per share.

2010

  • Dil Ltd declared Interim Dividend at Rs. 7.50/- per equity share.
  • Dil Ltd recommended final equity dividend at Rs. 7.50/- per equity share.

2011

  • Dil Ltd declared interim equity dividend at Rs. 15/- per equity share.
  • Dil Ltd recommended final equity dividend at Rs. 10/- per equity share.

2012

  • Dil Ltd declared interim equity dividend at Rs. 15/- per equity share.
  • Dil Ltd recommended final equity dividend at Rs. 15/- per equity share.

2013

  • Dil Ltd signed an Agreement with Advertising Agents and Consultants.

2014

  • The Board appointed Dr. Gopakumar Nair as an Additional Director of the company.

2016

  • Dil Ltd shifted its registered office to A -1601, Thane One, DIL Complex, Ghodbunder Road, Majiwade, Thane (West) 400 610, Maharashtra, India.

2018

  • The Company issued Bonus Shares in the Ratio of 1:1.

2019

  • The company name was changed to Fermenta Biotech Ltd. from DIL Ltd.

2020

  • The Company issued Bonus Shares in the Ratio of 2:1.

2021

  • Fermenta received the Pride of Maharashtra Awards 2021 as the Best Company of the Year for Excellence in Exports.
  • Fermenta was awarded as the runner up in the category Excellence in R&D for the Development of new Product/ technology in India Pharma Awards 2021.

2023

  • Fermenta received the Excellence in Logistics Performance - Pharma Award at the 5th India Logistics and Warehousing Excellence Awards 2023.

Open Your Free Demat Account Now!

Step into a world of zero fees and limitless opportunities!

pocketful logo

2022-25 Pocketful. All rights reserved, Built with in India

Version -5.76

app image 1app image 2

Stocks:

AllABCDEFGHIJKLMNOPQRSTUVWXYZ

Explore

Calculatorsfooter arrow down icon
Popular Calculatorsfooter arrow down icon
Group Stocksfooter arrow down icon
Asset Management Companiesfooter arrow down icon
Popular Stocksfooter arrow down icon
Indian Indicesfooter arrow down icon
Sector Wise Stocksfooter arrow down icon
IPOfooter arrow down icon
Share Marketfooter arrow down icon
Best MF Schemesfooter arrow down icon
Platformsfooter arrow down icon
Resourcesfooter arrow down icon

Others:

NSEBSECDSLNSDLSEBIMCXMSEINCDEXNSE IFSCINDIA INXAccount Closure FormDP Investor CharterBroker Investor Charter

Pocketful Fintech Capital Private Limited (CIN U65999DL2021PTC390548) | The SEBI Registration No. allotted to us is INZ000313732. NSE Member Code: 90326 | BSE Member Code: 6808 | MCX Member Code: 57120 DP | CDSL: 12099800